The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer

Preventive Medicine

Volumn 29, Issue 2, 1999, Pages 72-76

  Coogan, Patricia F ^a   Rao, Sowmya R ^a   Rosenberg, Lynn ^a   Palmer, Julie R ^a   Strom, Brian L ^b   Zauber, Ann G ^c   Stolley, Paul D ^d   Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Environmental factors; Epidemiology; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; PIROXICAM;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL;

EID: 0032818270     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1006/pmed.1999.0518     Document Type: Article

References (15)

1. Rosenberg L, Palmer J R, Zauber A G, Warshauer M E, Stolley P D, Shapiro S. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 83:1991;355-358.
2. Giovannucci E, Egan K M, Hunter D J, Stampfer M J, Colditz M D, Willett W C. Aspirin and the risk of colorectal cancer in women. New Engl J Med. 333:1995;609-614.
3. Peleg I I, Maibach H T, Brown S H, Wilcox M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 154:1994;394-399.
4. Muscat J E, Stellman S E, Wynder E L. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer. 74:1994;1847-1854.
5. Berkel H J, Holocombe R F, Middlebrooks M, Kannan K. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Epidemiol Rev. 18:1996;205-217.
6. Harris R E, Namboodiri K, Stellman, Wynder E L. Breast cancer and NSAID use: Heterogeneity of effect in a case-control study. Prev Med. 24:1995;119-120.
7. Harris R E, Namboodiri K K, Farrar W B. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology. 7:1996;203-205.
8. Schreinemachers D M, Everson R B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 5:1994;138-146.
9. Egan K M, Stampfer M J, Giovannucci E, Rosner B A, Colditz G A. Prospective study of regular aspirin use and risk of breast cancer. J Natl Cancer Inst. 88:1996;988-993.
10. Paganini-Hill A, Chao A, Ross R K, Henderson B E. Aspirin use and chronic diseases: A cohort study of the elderly. Br Med J. 299:1989;1247-1250.
11. Mehta R G, Moon R C. Characterization of effective chemopreventive agents in mammary gland in vitro with an initiation-promotion protocol. Anticancer Res. 11:1991;593-596.
12. Carter C A, Milholland R J, Shea W, Ip M M. Effect of the prosta glandin synthetase inhibitor indomethacin on 7,12-dimethyl benz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res. 43:1983;3559-3562.
13. McCormick D L, Madigan M J, Moon R C. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 45:1985;1803-1808.
14. McCormick D L, Wilson A M. Combination chemoprevention of rat mammary carcinogenesis by indomethacin and butylated hydroxytoluene. Cancer Res. 46:1986;3907-3911.
15. Thompson H G, Briggs S, Paranka N S, Piazza G A, Brendel K, Gross P H. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst. 87:1995;1259-1260.